Table 2 The questionnaires scores, urinary symptoms and uroflowmetry parameters in normal controls, non-treated and treated OAB groups before mirabegron treatment.

From: Urinary beta 3-adrenoceptor as a diagnostic biomarker for overactive bladder in women

 

Normal (n = 35)

Non-treated OAB (n = 27)

Treated OAB (n = 23)

p valuea

OABSS

4.83 ± 0.62

11.00 ± 2.62

12.00 ± 2.97

 < 0.001*#†

OAB-qSF symptom bother

6.57 ± 0.95

19.63 ± 8.24

24.52 ± 6.08

 < 0.001*#†

OAB-qSF HRQL

14.06 ± 2.35

44.07 ± 12.18

44.48 ± 9.36

 < 0.001*#†

SF-12

32.09 ± 1.27

32.19 ± 2.04

32.91 ± 2.04

0.108

GRAS

3.00 ± 0.00

3.00 ± 0.00

3.00 ± 0.00

1.000

Micturitions/24 h

7.34 ± 1.14

15.23 ± 6.73

15.65 ± 5.50

 < 0.001*#†

Urgency episodes/24 h

0.00 ± 0.00

1.67 ± 0.97

1.79 ± 0.84

 < 0.001*#†

Uroflowmetry

 Qmaxb (mL/s)

–

15.65 ± 6.99

13.67 ± 5.32

0.271

 Capacityc (mL)

–

285.65 ± 147.15

313.87 ± 145.13

0.471

 RUc (mL)

–

51.56 ± 74.39

56.17 ± 66.84

0.440

  1. Data are presented as mean ± standard deviation.
  2. OAB, Overactive bladder; OABSS, Overactive bladder symptom score; OAB-Qsf, Overactive bladder questionnaire short form; HRQL, Health-related quality of life scales; SF-12, Short Form Survey-12; GRAS, Global Response Assessment Scale; Qmax, Maximum flow rate; RU, Residual urine.
  3. aKruskal–Wallis test with Dunn's test.
  4. bStudent t-test.
  5. cMann–Whitney U-test.
  6. *p < 0.05.
  7. #p < 0.05 Normal vs Non-treated OAB.
  8. †p < 0.05 Normal vs Treated OAB.
Back to article page